Innovent Biologics ( (HK:1801) ) has provided an announcement.
Innovent Biologics, Inc. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board consists of both executive and independent non-executive directors, with Dr. De-Chao Michael Yu serving as the Chairman and CEO. This announcement underscores the company’s commitment to strong governance and strategic oversight, which is crucial for maintaining its competitive edge in the biopharmaceutical sector.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company incorporated in the Cayman Islands. It focuses on the development and commercialization of high-quality medicines, primarily targeting cancer, autoimmune, and other major diseases. The company is recognized for its innovative approach in the biopharmaceutical industry.
YTD Price Performance: 27.73%
Average Trading Volume: 14,200
Technical Sentiment Signal: Sell
Current Market Cap: $9.73B
For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.